CLRB News and Press, Cellectar Biosciences Inc. From 08/05/22

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quart...

Cellectar Biosciences ( NASDAQ: CLRB ) said it is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one new Common Share for every 10 currently outstanding. As of Thursday, the company will have about 6.1M shares outst...

FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that, as authorized by its stockholders, th...

Cellectar Biosciences press release (NASDAQ:CLRB): Q1 GAAP EPS of -$0.10 in-line. As of March 31, 2022, the company had cash and cash equivalents of $30.6 million, compared to $35.7 million as of December 31, 2021. Shares +3.07% PM. For further details see: Cellectar Biosciences GAAP EP...

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results ...

Cellectar Biosciences (NASDAQ:CLRB) on Tuesday said an independent committee recommended that the company continue its phase 2b study of its cancer therapy iopofosine to treat Waldenstrom’s macroglobulinemia (WM), a rare type of cancer that begins in the white blood cells. CLRB said an...

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced an independent D...

Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharma...

Cellectar Biosciences Inc. (NASDAQ:CLRB) traded today at a new 52-week high of $14.46. This new high was reached on above average trading volume as 106.2 million shares traded hands, while the average 30-day volume is approximately 173,000 shares. In the past 52 weeks, Cellectar Bioscien...

Cellectar Biosciences press release (NASDAQ:CLRB): FY GAAP EPS of -$0.43 beats by $0.01. As of December 31, 2021, the company had cash and cash equivalents of $35.7 million, compared to $57.2 million at December 31, 2020. For further details see: Cellectar Biosciences GAAP EPS...